September 27, 2015Open Access

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Borghaei et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69d7218aef370a38abf50ccc — DOI: https://doi.org/10.1056/nejmoa1507643

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer· 2015 · 8,522 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma· 2010 · 15,098 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,244 citations
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Authors

H. Borghaei

L. Paz-Ares

Leora Horn

Journals

New England Journal of Medicine

Actions

Institutions

University of Washington

University of Chicago

Memorial Sloan Kettering Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion